Sponsor

Avexa

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Avexa appears in 6 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials6
Recruiting shown0
Roles1
SourceClinicalTrials.gov
Advertisement

Clinical trials

6 shown
A Long Term Safety Study of Apricitabine in HIV-infected PatientsNCT00686270 · lead sponsor · 2008-05-01
WITHDRAWN
Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV InfectionNCT00612898 · lead sponsor · 2008-02-01
TERMINATED
A Long Term, Safety Study of Apricitabine in HIV-infected SubjectsNCT00367952 · lead sponsor · 2006-08-01
COMPLETED
Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or TogetherNCT00352066 · lead sponsor · 2006-07-01
COMPLETED
A Study to Investigate the Cardiovascular Safety of Apricitabine in Healthy SubjectsNCT00334659 · lead sponsor · 2006-06-01
COMPLETED
AVX754 (a New Nucleoside Reverse Transcriptase Inhibitor [NRTI]) to Treat Drug-resistant HIVNCT00126880 · lead sponsor · 2005-07-01
COMPLETED

Sponsor roles

lead sponsor6

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.